Today it was reported that the CEO of Galectin Therapeutics (GALT), Harold Shlevin, exercised options to buy 8,706 GALT shares at $1.37 a share, for a total transaction value of $11.93K.
This recent transaction increases Harold Shlevin’s holding in the company by 100% to a total of $35.26K. In addition to Harold Shlevin, 7 other GALT executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
The Company has a Price to Book ratio of 39.2079. Currently, Galectin Therapeutics has an average volume of 226.3K.
Starting in August 2018, GALT received 10 Buy ratings in a row.
The insider sentiment on Galectin Therapeutics has been positive according to 41 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs targets the development of carbohdrate molecules which offers offer alternative options to larger market segments.
